LXN and melanoma: High LXN expression in the melanoma specimens correlated with shortened patient survival (age-adjusted HR 4.0, 95%-CI [1.8;9.1]; p = 0.001), with a 5-year survival of 88.9% (95%-CI [75.3;95.2]) in the LXN low patients in comparison with 55.0% (95%-CI [41.6;66.5]) for the LXN high patients (Fig. 5A).